Two new molecular entities, Lundbeck's Selincro (nalmefene) for the treatment of alcoholism and Roche's Perjeta (pertuzumab) for breast cancer, and a new antipsychotic formulation, Alexza Pharmaceuticals Inc.'s Adasuve (inhaled loxapine) were granted positive opinions Dec. 14 by Europe's Committee for Medicinal Products for Human Use (CHMP).
However, [Genzyme BV]/Ionis Pharmaceuticals Inc.'s antisense lipid-lowering therapy Kynamro (mipomersen) and Vanda Pharmaceuticals Inc.’s atypical antipsychotic Fanaptum (oral...